Oral Drug Mezigdomide Improves Outcomes for Relapsed Multiple Myeloma

A Phase 3 clinical trial indicates that the oral drug mezigdomide, when added to standard therapy, significantly extends progression-free survival for patients with relapsed or refractory multiple myeloma. This novel CELMoD works by targeting protein degradation and activating the immune system. The findings suggest a potential new standard of care for patients with limited treatment options.